Stocktoria
PTC THERAPEUTICS, INC. PTCT
PTC THERAPEUTICS, INC. (PTCT) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the grey zone. It does not currently pay a dividend. FY2025 revenue was $1.7B at a 39.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-05-27 | Jefferies | Buy (up) |
| 2026-05-08 | TD Cowen | Buy (up) |
| 2026-05-08 | RBC Capital | Sector Perform (main) |
| 2026-05-08 | Wells Fargo | Overweight (main) |
| 2026-03-30 | Jefferies | Hold (down) |
| 2026-02-23 | Morgan Stanley | Overweight (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | 0.45 |
| Retained earnings / assets | -1.023 |
| EBIT / assets | 0.299 |
| Equity / liabilities | -0.066 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| PTCT | PTC THERAPEUTICS, INC. | 5/9 | 1.56 | 10.3 | +114.5% |
| ALKS | Alkermes plc. | 5/9 | 6.24 | 38 | -5.2% |
| PAHC | PHIBRO ANIMAL HEALTH CORP | 5/9 | 3.97 | 26.6 | +27.4% |
| SRPT | Sarepta Therapeutics, Inc. | 4/9 | -2.78 | — | +15.6% |
| INDV | Indivior Pharmaceuticals, Inc. | 4/9 | -0.7 | 24.3 | +4.3% |
| NSRX | Nasus Pharma Ltd | 3/9 | -13.82 | — | — |
| PBH | Prestige Consumer Healthcare Inc. | 5/9 | 4.04 | 12.3 | -4.3% |
About PTC THERAPEUTICS, INC.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
FAQ
Is PTCT financially healthy?
PTC THERAPEUTICS, INC.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does PTCT pay a dividend?
No, PTC THERAPEUTICS, INC. does not currently pay a dividend.
How profitable is PTCT?
In FY2025, PTC THERAPEUTICS, INC. had a net margin of 39.4%.
What is PTCT's P/E ratio?
PTC THERAPEUTICS, INC.'s trailing price-to-earnings (P/E) ratio is about 10.3×, based on its latest annual earnings.
What is the analyst price target for PTCT?
The average Wall-Street price target for PTC THERAPEUTICS, INC. is $93.93, about 29.3% above the recent price, from 14 analysts.
Is PTCT a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on PTC THERAPEUTICS, INC.: a Piotroski F-score of 5/9, an Altman Z″ in the grey zone, a P/E of about 10.3×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.